LVTX · Insider Trading
LAVA Therapeutics N.V. Ordinary Shares
Every open-market purchase and sale reported by LVTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-11-17 | Karen J Wilson | Director | D | −10,000 | — |
| 2025-11-17 | Mary E. Wadlinger | Director | D | −33,390 deriv. | — |
| 2025-11-17 | Kapil Dhingra | Director | D | −30,000 | — |
| 2025-11-17 | James Noble | Director | D | −33,390 deriv. | — |
| 2025-11-17 | Jay T. Backstrom | Director | D | −33,390 deriv. | — |
| 2025-11-17 | Peter A Kiener | Director | D | −33,390 deriv. | — |
| 2025-11-17 | Christy J. Oliger | Director | D | −33,390 deriv. | — |
| 2025-11-17 | Fred M Powell | Chief Financial Officer | D | −65,000 | — |
| 2025-11-17 | Stephen A Hurly | Chief Executive Officer | D | −5,000 | — |
| 2025-10-20 | Gilde Healthcare IV U.A. Cooperatieve | 10%+ Owner | Sell | −5,742,740 | −$8.45M |
| 2025-10-15 | Gilde Healthcare IV U.A. Cooperatieve | 10%+ Owner | Sell | −950,054 | −$1.44M |
| 2025-10-10 | Gilde Healthcare Holding B.V. | 10%+ Owner | Sell | −253,984 | −$395.80K |
| 2025-09-23 | Versant Ventures VI GP, L.P. | 10%+ Owner | Sell | −17,420,418 | −$24.41M |
| 2025-09-18 | Versant Vantage I, L.P. | 10%+ Owner | Sell | −10,106,604 | −$15.01M |
| 2025-02-18 | Christy J. Oliger | Director | A | +33,390 deriv. | — |
| 2025-02-18 | Kapil Dhingra | Director | A | +33,390 deriv. | — |
| 2025-02-18 | Charles Q Morris | Chief Medical Officer | A | +130,850 deriv. | — |
| 2025-02-18 | Peter A Kiener | Director | A | +33,390 deriv. | — |
| 2025-02-18 | Karen J Wilson | Director | A | +33,390 deriv. | — |
| 2025-02-18 | Fred M Powell | Chief Financial Officer | A | +124,700 deriv. | — |
| 2025-02-18 | Jay T. Backstrom | Director | A | +33,390 deriv. | — |
| 2025-02-18 | Stephen A Hurly | Chief Executive Officer | A | +335,100 deriv. | — |
| 2025-02-18 | James Noble | Director | A | +33,390 deriv. | — |
| 2025-02-18 | Mary E. Wadlinger | Director | A | +33,390 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Gilde Healthcare Holding B.V. | 10%+ Owner | 5,294,178 | $9.21M |
| Gilde Healthcare IV U.A. Cooperatieve | 10%+ Owner | 4,128,912 | $7.18M |
| Versant Vantage I, L.P. | 10%+ Owner | 3,358,920 | $5.84M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LVTX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.